i-SENS Inc (099190) - Cash Flow Conversion Efficiency
Based on the latest financial reports, i-SENS Inc (099190) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.18 Billion ≈ $4.19 Million USD) by net assets (₩345.35 Billion ≈ $234.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
i-SENS Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how i-SENS Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read i-SENS Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
i-SENS Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of i-SENS Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Catella AB (publ)
ST:CAT-B
|
0.009x |
|
United Pharm
KO:033270
|
0.051x |
|
Quang Viet Enterprise Co Ltd
TW:4438
|
-0.025x |
|
SNS
KLSE:0259
|
-0.411x |
|
Atomera Inc
NASDAQ:ATOM
|
-0.175x |
|
Aurora Cannabis Inc
NASDAQ:ACB
|
0.030x |
|
Samara Asset Group
F:SRAG
|
N/A |
|
Mechema Chemicals Int
TWO:4721
|
0.108x |
Annual Cash Flow Conversion Efficiency for i-SENS Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of i-SENS Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see i-SENS Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩342.98 Billion ≈ $232.43 Million |
₩22.96 Billion ≈ $15.56 Million |
0.067x | +55.73% |
| 2023-12-31 | ₩303.49 Billion ≈ $205.67 Million |
₩13.05 Billion ≈ $8.84 Million |
0.043x | +84.64% |
| 2022-12-31 | ₩285.81 Billion ≈ $193.69 Million |
₩6.65 Billion ≈ $4.51 Million |
0.023x | -63.73% |
| 2021-12-31 | ₩268.33 Billion ≈ $181.84 Million |
₩17.22 Billion ≈ $11.67 Million |
0.064x | -59.30% |
| 2020-12-31 | ₩219.49 Billion ≈ $148.75 Million |
₩34.61 Billion ≈ $23.46 Million |
0.158x | -17.49% |
| 2019-12-31 | ₩198.56 Billion ≈ $134.56 Million |
₩37.95 Billion ≈ $25.72 Million |
0.191x | +76.94% |
| 2018-12-31 | ₩180.93 Billion ≈ $122.61 Million |
₩19.54 Billion ≈ $13.24 Million |
0.108x | -21.41% |
| 2017-12-31 | ₩162.80 Billion ≈ $110.32 Million |
₩22.38 Billion ≈ $15.16 Million |
0.137x | +75.44% |
| 2016-12-31 | ₩149.67 Billion ≈ $101.43 Million |
₩11.73 Billion ≈ $7.95 Million |
0.078x | -54.15% |
| 2015-12-31 | ₩132.02 Billion ≈ $89.47 Million |
₩22.56 Billion ≈ $15.29 Million |
0.171x | +13.76% |
| 2014-12-31 | ₩118.81 Billion ≈ $80.51 Million |
₩17.85 Billion ≈ $12.09 Million |
0.150x | -3.22% |
| 2013-12-31 | ₩104.32 Billion ≈ $70.70 Million |
₩16.19 Billion ≈ $10.97 Million |
0.155x | +108.16% |
| 2012-12-31 | ₩68.44 Billion ≈ $46.38 Million |
₩5.10 Billion ≈ $3.46 Million |
0.075x | -- |
About i-SENS Inc
i-SENS, Inc. provides diagnostic biosensors in South Korea. The company offers point of care testing devices, such as HbA1c, blood gas, electrolyte, and PT/INR analyzers; CareSens blood glucose monitoring systems; and lancing and other ancillary devices, as well as diabetes management services. It exports its products to approximately 110 countries, including the United States, Japan, and Europe.… Read more